OPC 41061 IN PATIENTS W/ HYPONATREMIA

OPC 41061 用于低钠血症患者

• 批准号: 6265269
• 负责人: Helmy M Siragy
• 金额: $ 2.81万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265269
• 关键词: arginine vasopressin; benzazepines; clinical research; clinical trial phase I; dosage; drug screening /evaluation; health services research tag; hormone receptor; hormone regulation /control mechanism; hospital utilization; human subject; human therapy evaluation; hyponatremia; inhibitor /antagonist; kidney disorder chemotherapy; kidney function; vasopressins

Hyponatremia is a frequently encountered electrolyte disorder which can produce severe neurological complications. Excretion of free water by the kidney is often impaired. In many instances, this results from increased levels of circulating arginine vasopressin (AVP), an antidiuretic hormone (ADH).The purpose of this protocol is to assess the efficacy, safety, and dose characteristcs of titrated doses of OPC-41061, a vasopressin V-2 receptor antagonist in hospitalized patients with hyponatremia. Recruitment continues.

低钠血症是一种经常遇到的电解质疾病，可产生严重的神经系统并发症。 肾脏从肾脏中排泄自由水经常受到损害。 在许多情况下，这是由于循环精氨酸加压素（AVP）的水平增加，一种抗利尿激素（ADH）。该方案的目的是评估滴定剂量的OPC-41061滴定剂量的功效，安全性和剂量特征，一种血管皮蛋白V-2受体拮抗剂在医院化的患者中。招聘仍在继续。